BrainLAB opens new gateway to high-dose radiotherapy
This article was originally published in Clinica
Executive Summary
Targeting high-dose radiotherapy at liver and lung tumours is now a possibility using BrainLAB's ExacTrac X-Ray Adaptive Gating system. Such levels of radiation are traditionally difficult to administer to these tumours, due to respiration-induced movement and the risk of damaging sensitive surrounding tissue. But the Munich, Germany-based company has overcome this problem, and has announced the completion of the first patient treatment programme using the system - carried out with its clinical partners AZ-VUB of Brussels, Belgium.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.